C24:1 β-Glucosylceramide
| Product Name | C24:1 β-Glucosylceramide |
|---|---|
| Alternate Names | - Carbohydrates, Carbohydrates of - |
| CAT No. | CS-O-51516 |
| CAS No. | 887907-50-8 |
| Category | Carbohydrates |
| Stock | Enquire |
| Mol. Wt. | 810.24 g/mol |
| Mol. For. | C48H91NO8 |
| Hazardous | This is not a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | - |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Get an Instant Quote
Related Compounds
GT3Cer d18:1/24:1 (Neu5Aca2,8Neu5Aca2,8Neu5Aca2,3Galb1,4GlcbCeramide) | Blood type tetrasaccharide A Type VI | LacNAc PEG-NH2 | GT2Cer d20:1/18:0 (GalNAcb1,4(Neu5Aca2,8Neu5Aca2,8Neu5Aca2,3)Galb1,4GlcbCeramide) | GM3Cer d20:1/18:0 (Neu5Aca2,3Galb1,4GlcbCeramide) | GlcCer d20:1/18:0 (GlcbCeramide) | FucGM1Cer d18:1/8:0 ((Fuca1,2)Galb1,3GalNAcb1,4(Neu5Aca2,3)Galb1,4GlcbCeramide) | GM2Cer d18:1/16:0 (GalNAcb1,4(Neu5Aca2,3)Galb1,4GlcbCeramide) | Glucobrassicine | FucGM1sph d18:1 ((Fuca1,2)Galb1,3GalNAcb1,4(Neu5Aca2,3)Galb1,4GlcbSphingolipids) | GT3Cer d20:1/12:0 (Neu5Aca2,8Neu5Aca2,8Neu5Aca2,3Galb1,4GlcbCeramide) | GD2Cer d18:1/16:0 (GalNAcb1,4(Neu5Aca2,8Neu5Aca2,3)Galb1,4GlcbCeramide) | Gala1, 4Galb1, 4Glc | GT1cCer d20:1/24:1 (Galb1,3GalNAcb1,4(Neu5Aca2,8Neu5Aca2,8Neu5Aca2,3)Galb1,4GlcbCeramide) | GM3sph d20:1 (Neu5Aca2,3Galb1,4GlcbSphingolipids) | Galc d18:1/18:0（GalaCeramide） | GT2sph d18:1 (GalNAcb1,4(Neu5Aca2,8Neu5Aca2,8Neu5Aca2,3)Galb1,4GlcbSphingolipids) | GD2 | Lewis A (Lea ) pentasaccharide | GT1cCer d18:1/8:0 (Galb1,3GalNAcb1,4(Neu5Aca2,8Neu5Aca2,8Neu5Aca2,3)Galb1,4GlcbCeramide) | GM2Cer d18:1/16:0 (GalNAcb1,4(Neu5Aca2,3)Galb1,4GlcbCeramide) | GM1bCer d18:1/18:0-Biotin ((Neu5Aca2,3)Galb1,3GalNAcb1,4Galb1,4GlcbCeramide-Biotin) | Sialyl-Lc4 | GT3Cer d18:1/20:0 (Neu5Aca2,8Neu5Aca2,8Neu5Aca2,3Galb1,4GlcbCeramide) | GT3Cer d20:1/16:0 (Neu5Aca2,8Neu5Aca2,8Neu5Aca2,3Galb1,4GlcbCeramide) | GM2sph d18:1 (GalNAcb1,4(Neu5Aca2,3)Galb1,4GlcbSphingolipids) | GT3Cer d20:1/8:0 (Neu5Aca2,8Neu5Aca2,8Neu5Aca2,3Galb1,4GlcbCeramide) | GM1aCer d18:1/24:1 (Galb1,3GalNAcb1,4(Neu5Aca2,3)Galb1,4GlcbCeramide) | GD2Cer d18:1/12:0 (GalNAcb1,4(Neu5Aca2,8Neu5Aca2,3)Galb1,4GlcbCeramide) | GT3Cer d18:1/18:0 (Neu5Aca2,8Neu5Aca2,8Neu5Aca2,3Galb1,4GlcbCeramide) | iGloboHCer d18:1/18:0-Biotin ((Fuca1,2)Galb1,3GalNAcb1,3Gala1,3Galb1,4GlcbCeramide-Biotin) | Lactose PEG-NH2 | Ac7 Lactose-PEG-N3 | GM1bCer d20:1/18:0 (Neu5Aca2,3Galb1,3GalNAcb1,4Galb1,4GlcbCeramide) | FucGM1Cer d20:1/8:0 ((Fuca1,2)Galb1,3GalNAcb1,4(Neu5Aca2,3)Galb1,4GlcbCeramide) | GQ3Cer d18:1/12:0 (Neu5Aca2,8Neu5Aca2,8Neu5Aca2,8Neu5Aca2,3Galb1,4GlcbCeramide) | Neu5Gca2-3Lea-sp-biotin | GD1aCer d20:1/16:0 ((Neu5Aca2,3)Galb1,3GalNAcb1,4(Neu5Aca2,3)Galb1,4GlcbCeramide) | GM1aCer d18:1/18:0 (Galb1,3GalNAcb1,4(Neu5Aca2,3)Galb1,4GlcbCeramide) | GD3Cer d20:1/18:0 (Neu5Aca2,8Neu5Aca2,3Galb1,4GlcbCeramide) | Neu5Aca2,3Galb1,4(Fuca1,3)(HSO4-6-)GlcNAc | GM2 | GM1bCer d18:1/12:0 (Neu5Aca2,3Galb1,3GalNAcb1,4Galb1,4GlcbCeramide) | GD3 | FucGM1Cer d18:1/16:0 ((Fuca1,2)Galb1,3GalNAcb1,4(Neu5Aca2,3)Galb1,4GlcbCeramide) | iGB3Cer d18:1/18:0-Biotin (Gala1,3Galb1,4GlcbCeramide-Biotin) | GD1bCer d18:1/8:0 (Galb1,3GalNAcb1,4(Neu5Aca2,8Neu5Aca2,3)Galb1,4GlcbCeramide) | GlcCer d18:1/20:0 (GlcbCeramide) | B-Antigen-Cer d18:1/18:0-Biotin (Gala1,3(Fuca1,2)Galb1,4GlcbCeramide-Biotin) | Zymosan | Blood type trisaccharide H Type VI (2'FL) | FucGM1Cer d20:1/20:0 ((Fuca1,2)Galb1,3GalNAcb1,4(Neu5Aca2,3)Galb1,4GlcbCeramide) | GD1bCer d20:1/16:0 (Galb1,3GalNAcb1,4(Neu5Aca2,8Neu5Aca2,3)Galb1,4GlcbCeramide) | GM1bCer d18:1/20:0 (Neu5Aca2,3Galb1,3GalNAcb1,4Galb1,4GlcbCeramide) | GQ3sph d18:1 (Neu5Aca2,8Neu5Aca2,8Neu5Aca2,8Neu5Aca2,3Galb1,4GlcbSphingolipids) | GM3Cer d20:1/20:0 (Neu5Aca2,3Galb1,4GlcbCeramide) | Neu5Gca2, 3Galb1, 4GlcNAc | GT1csph d20:1 (Galb1,3GalNAcb1,4(Neu5Aca2,8Neu5Aca2,8Neu5Aca2,3)Galb1,4GlcbSphingolipids) | Sialyl-iGB5Cer d18:1/18:0-Biotin ((Neu5Aca2,3)Galb1,3GalNAcb1,3Gala1,3Galb1,4GlcbCeramide-Biotin) | Neoglucobrassicin | P(Galb1,3Gala1,4Galb1,4GlcbR) | GloboHCer d18:1/18:0-Biotin ((Fuca1,2)Galb1,3GalNAcb1,3Gala1,4Galb1,4GlcbCeramide-Biotin) | GalNAcb1, 4Galb1, 4GlcNAc | GD2Cer d18:1/24:1 (GalNAcb1,4(Neu5Aca2,8Neu5Aca2,3)Galb1,4GlcbCeramide) | GM2Cer d18:1/12:0 (GalNAcb1,4(Neu5Aca2,3)Galb1,4GlcbCeramide) | FucGM1Cer d18:1/24:1 ((Fuca1,2)Galb1,3GalNAcb1,4(Neu5Aca2,3)Galb1,4GlcbCeramide) | GM1aCer d20:1/16:0 (Galb1,3GalNAcb1,4(Neu5Aca2,3)Galb1,4GlcbCeramide) | GalNAcb1, 3Gal | Bortezomib D-mannitol | GD3Cer d20:1/16:0 (Neu5Aca2,8Neu5Aca2,3Galb1,4GlcbCeramide) |